A selectable and excisable marker system for the rapid creation of recombinant poxviruses

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Rintoul, Julia L ^a,b   Wang, Jiahu ^b   Gammon, Don B ^c   van Buuren, Nicholas J ^c   Garson, Kenneth ^b   Jardine, Karen ^b   Barry, Michele ^c   Evans, David H ^c   Bell, John C ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; HYBRID PROTEIN;

ARTICLE; CONTROLLED STUDY; ECTROMELIA VIRUS; EVM002 GENE; GENE; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; GENE INSERTION; GENETIC PARAMETERS; GUANINE PHOSPHORIBOSYLTRANSFERASE GENE; LOXP SITE; MARKER GENE; NONHUMAN; POXVIRUS; REPORTER GENE; SELECTABLE AND EXCISABLE MARKER SYSTEM; SPECIES DIFFERENCE; SYSTEM ANALYSIS; VACCINIA VIRUS; VIRUS GENOME; VIRUS RECOMBINANT; YELLOW FLUORESCENT PROTEIN GENE; ANIMAL; CATTLE; CELL LINE; CERCOPITHECUS; GENE VECTOR; GENETIC MARKER; GENETIC RECOMBINATION; GENETICS; HUMAN; TUMOR CELL LINE;

ECTROMELIA VIRUS; POXVIRIDAE; VACCINIA VIRUS;

ANIMALS; CATTLE; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; GENETIC MARKERS; GENETIC VECTORS; HUMANS; POXVIRIDAE; RECOMBINATION, GENETIC;

EID: 80052519745     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024643     Document Type: Article

References (47)

1. Fenner F, HendersonA D, Arita L, Jezek Z, Ladnyi ID, eds. (1988) Smallpox and Its Eradication Geneva W.H.O.
2. Gilbert PA, McFadden G, (2006) Poxvirus cancer therapy. Recent Pat Antiinfect Drug Discov 1: 309-321.
3. Moroziewicz D, Kaufman HL, (2005) Gene therapy with poxvirus vectors. Curr Opin Mol Ther 7: 317-325.
4. Smith GL, Moss B, (1983) Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 25: 21-28.
5. Fenner F, Comben BM, (1958) [Genetic studies with mammalian poxviruses. I. Demonstration of recombination between two strains of vaccina virus.]. Virology 5: 530-548.
6. Nakano E, Panicali D, Paoletti E, (1982) Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A 79: 1593-1596.
7. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, et al. (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6: 409-422.
8. Erbs P, Findeli A, Kintz J, Cordier P, Hoffmann C, et al. (2008) Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther 15: 18-28.
9. Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, et al. (1992) Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 339: 1429-1432.
10. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, et al. (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28: 1099-1105.
11. Kanesa-thasan N, Smucny JJ, Hoke CH, Marks DH, Konishi E, et al. (2000) Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 19: 483-491.
12. Bejon P, Ogada E, Mwangi T, Milligan P, Lang T, et al. (2007) Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS One 2: e707.
13. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, et al. (2007) Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 13: 4487-4494.
14. Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW Jr, Chatterjee SK, (2006) Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma. Mol Ther 13: 183-193.
15. Lorenz MG, Kantor JA, Schlom J, Hodge JW, (1999) Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum Gene Ther 10: 1095-1103.
16. Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, et al. (2010) Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res 70: 598-608.
17. Evgin L, Vaha-Koskela M, Rintoul J, Falls T, Le Boeuf F, et al. (2010) Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Mol Ther 18: 896-902.
18. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, et al. (1996) Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 2: 893-898.
19. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, et al. (2006) Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 14: 361-370.
20. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, et al. (2001) Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61: 8751-8757.
21. Mackett M, Smith GL, Moss B, (1984) General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 49: 857-864.
22. Piccini A, Perkus ME, Paoletti E, (1987) Vaccinia virus as an expression vector. Methods Enzymol 153: 545-563.
23. Gammon DB, Gowrishankar B, Duraffour S, Andrei G, Upton C, et al. (2010) Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis. PLoS Pathog 6: e1000984.
24. Franke CA, Rice CM, Strauss JH, Hruby DE, (1985) Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants. Mol Cell Biol 5: 1918-1924.
25. Falkner FG, Moss B, (1988) Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 62: 1849-1854.
26. Chakrabarti S, Brechling K, Moss B, (1985) Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 5: 3403-3409.
27. Carroll MW, Moss B, (1995) E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. Biotechniques 19: 352-354, 356.
28. Luker KE, Hutchens M, Schultz T, Pekosz A, Luker GD, (2005) Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 341: 284-300.
29. Committee for the Proprietary Medicinal Products (CPMP). Note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products, The European Agency for the Evaluation of Medicinal Products, (London, 2001). EMA website. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500003987.pdf. Accessed 2011 Aug 18.
30. Demmin GL, Clase AC, Randall JA, Enquist LW, Banfield BW, (2001) Insertions in the gG gene of pseudorabies virus reduce expression of the upstream Us3 protein and inhibit cell-to-cell spread of virus infection. J Virol 75: 10856-10869.
31. Falkner FG, Moss B, (1990) Transient dominant selection of recombinant vaccinia viruses. J Virol 64: 3108-3111.
32. Scheiflinger F, Dorner F, Falkner FG, (1998) Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus. Arch Virol 143: 467-474.
33. Alejo A, Saraiva M, Ruiz-Arguello MB, Viejo-Borbolla A, de Marco MF, et al. (2009) A method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants. PLoS One 4: e5175.
34. Gammon DB, Evans DH, (2009) The 3′-to-5′ exonuclease activity of vaccinia virus DNA polymerase is essential and plays a role in promoting virus genetic recombination. J Virol 83: 4236-4250.
35. Sauer B, Henderson N, (1988) Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci U S A 85: 5166-5170.
36. Sternberg N, Hamilton D, (1981) Bacteriophage P1 site-specific recombination. I. Recombination between loxP sites. J Mol Biol 150: 467-486.
37. Xiang H, Wang J, Boxer LM, (2006) Role of the cyclic AMP response element in the bcl-2 promoter in the regulation of endogenous Bcl-2 expression and apoptosis in murine B cells. Mol Cell Biol 26: 8599-8606.
38. Shor B, Cavender D, Harris C, (2009) A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice. BMC Immunol 10: 28.
39. Shearwin KE, Callen BP, Egan JB, (2005) Transcriptional interference-a crash course. Trends Genet 21: 339-345.
40. Isaacs SN, Kotwal GJ, Moss B, (1990) Reverse guanine phosphoribosyltransferase selection of recombinant vaccinia viruses. Virology 178: 626-630.
41. Lin YC, Li J, Irwin CR, Jenkins H, DeLange L, et al. (2008) Vaccinia virus DNA ligase recruits cellular topoisomerase II to sites of viral replication and assembly. J Virol 82: 5922-5932.
42. Gu H, Zou YR, Rajewsky K, (1993) Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 73: 1155-1164.
43. Chakrabarti S, Sisler JR, Moss B, (1997) Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23: 1094-1097.
44. Zhu B, Cai G, Hall EO, Freeman GJ, (2007) In-fusion assembly: seamless engineering of multidomain fusion proteins, modular vectors, and mutations. Biotechniques 43: 354-359.
45. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, et al. (1995) A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 23: 628-633.
46. Meyer H, Damon IK, Esposito JJ, (2004) Orthopoxvirus diagnostics. Methods Mol Biol 269: 119-134.
47. Krumsiek J, Arnold R, Rattei T, (2007) Gepard: a rapid and sensitive tool for creating dotplots on genome scale. Bioinformatics 23: 1026-1028.